

and care by 2025. International journal of geriatric psychiatry. 2018;33(7):900-906.

9. Bradshaw AC, Georges J. Anti-Amyloid Therapies for Alzheimer's Disease: An Alzheimer Europe Position Paper and Call to Action. The Journal of Prevention of Alzheimer's Disease. 2024;11(2):265-273.

10. Wojtunik-Kulesza K, Rudkowska M, Orzel-Sajdłowska A. Aducanumab – hope or disappointment for Alzheimer's disease. International Journal of Molecular Sciences. 2023;24(5):4367.

11. Heidebrink JL, Paulson HL. Lessons Learned from Approval of Aducanumab for Alzheimer's Disease. Annual Review of Medicine. 2024;75:99-111.

12. Monfared AAT, Ye W, Sardesai A, et al. A path to improved Alzheimer's care: simulating long-term health outcomes of

lecanemab in early Alzheimer's disease from the CLARITY AD trial. Neurology and Therapy. 2023;12(3):863-881.

13. Volloch V, Rits-Volloch S. Effect of lecanemab in early Alzheimer's disease: mechanistic interpretation in the amyloid cascade hypothesis 2.0 perspective. Journal of Alzheimer's Disease. 2023;93(4):1277-1284.

14. Cohen S, van Dyck SH, Gee M, et al. Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, Double-Blind Phase 3 Trial in Early Alzheimer's Disease. The Journal of Prevention of Alzheimer's disease. 2023;10(4):771-777.

15. Sims JR, Zimmer JA, Evans CD, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023;330(6):512-527.

16. Cummings J, Cammann D, Powell J, et al. Anti-amyloid

monoclonal antibodies for the treatment of Alzheimer's disease. BioDrugs. 2024;38(1):5-22.

17. Atri A, Wessels A, Doty E, et al. Clinical Relevance of Donanemab Treatment (S1. 004). Neurology. Hagerstown, MD: Lippincott Williams & Wilkins, 2024;102:17(supplement 1).

18. Hampel H, Elhage A, Cho M, et al. Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. Brain. 2023;146(11):4414-4424.

19. Holmerová I, Baláčková N, Baumanová M, et al. Strategie České alzheimerovské společnosti P-PA-IA. Geriatrie a gerontologie. 2013;2(3):158-164.

20. Holmerová I. Case management v péči o lidi žijící s demencí: koordinace péče zaměřená na člověka. Fakulta humanitních studií Univerzity Karlovy, 2018.

Připravujeme do Pediatrie pro praxi

2024
3

- Importance and safety of magnesium supplementation in pregnancy. Supplement or not?
- Prehľad liekových interakcií u pacientov s kardiovaskulárnymi ochoreniami a diabetom 2. typu pri podávaní nirmatrelviru/ritonaviru
- Vazebné síly: typy interakcí léčiv s jejich cílovými strukturami v organismu
- Současné trendy v terapii bolesti u popálených pacientů. Opioidní, neopioidní a nefarmakologické ovlivnění bolesti



VYJDE
V
ŘÍJNU

 **SOLEN**
let s vámi